Table 2 Clinical characteristics used in the calculation of the risk score and the association with obesity status
Clinical Characteristics | Factor in risk score calculation | Obese (n = 383) | Overweight (n = 820) | Normal Weight (n = 373) | F or Chi-Square p-Value | |
|---|---|---|---|---|---|---|
Kattan | CaPSURE/CPDR | |||||
Pre-surgery PSA ng/mL, mean, SD | X | X | 6.3, 6.2 | 6.1, 5.7 | 6.1, 6.5 | 0.861 |
Pathological staging | ||||||
Extracapsular Extension, N (%) | X | X | 125 (32.6) | 204 (24.9) | 87 (23.3) | 0.005 |
Seminal Vesicle Invasion, N (%) | X | 37 (9.7) | 43 (5.2) | 29 (7.8) | 0.016 | |
Lymph Node, N (%) | X | 6 (1.6) | 6 (0.7) | 0 (0.0) | 0.045 | |
Pathological Gleason Score | X | 6.7, 0.8 | 6.5, 0.8 | 6.5, 0.9 | 0.001 | |
Pathological Gleason Grade1 ≥ 4, N (%) | X | 57 (14.9) | 87 (10.6) | 34 (9.1) | 0.045 | |
Pathological Gleason Grade 2 ≥ 4, N (%) | X | 145 (37.9) | 252 (30.7) | 101 (27.1) | 0.019 | |
Surgery Year, range | X | 1990–2014 | 1989–2015 | 1987–2014 | ||
Surgical Margin, N (%) | X | 87 (22.7) | 154 (18.8) | 54 (14.5) | 0.016 | |
Adjuvant Radiotherapy, N (%) | X | 24 (6.3) | 34 (4.2) | 10 (2.7) | 0.050 | |
African American, N (%) | X | 103 (26.9) | 160 (19.5) | 59 (15.8) | .001 | |